|Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer|
M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ...
Journal of clinical oncology 21 (12), 2237-2246, 2003
|First-line crizotinib versus chemotherapy in ALK-positive lung cancer|
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
|Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials|
JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ...
The Lancet Oncology 16 (6), 630-637, 2015
|Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer|
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ...
Nature genetics 44 (10), 1104-1110, 2012
|Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial|
H Van Tinteren, OS Hoekstra, EF Smit, JHAM Van Den Bergh, ...
The Lancet 359 (9315), 1388-1392, 2002
|Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
D Planchard, S Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ...
Annals of Oncology 29, iv192-iv237, 2018
|Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer|
J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ...
Science translational medicine 2 (62), 62ra93-62ra93, 2010
|Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer|
JP Van Meerbeeck, GWPM Kramer, PEY Van Schil, C Legrand, EF Smit, ...
Journal of the National Cancer Institute 99 (6), 442-450, 2007
|Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non–small-cell lung cancer|
FJ Lagerwaard, CJA Haasbeek, EF Smit, BJ Slotman, S Senan
International Journal of Radiation Oncology* Biology* Physics 70 (3), 685-692, 2008
|RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics|
MG Best, N Sol, I Kooi, J Tannous, BA Westerman, F Rustenburg, ...
Cancer cell 28 (5), 666-676, 2015
|Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial|
D Planchard, EF Smit, HJM Groen, J Mazieres, B Besse, Å Helland, ...
The Lancet Oncology 18 (10), 1307-1316, 2017
|Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial|
DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ...
Journal of Clinical Oncology 35 (22), 2490-2498, 2017
|Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …|
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
|Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European …|
EF Smit, J Van Meerbeeck, P Lianes, C Debruyne, C Legrand, ...
Journal of Clinical Oncology 21 (21), 3909-3917, 2003
|2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up|
J Vansteenkiste, L Crinò, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ...
Annals of Oncology 25 (8), 1462-1474, 2014
|Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor–resistant EGFR-mutant lung cancer with and without T790M mutations|
YY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ...
Cancer discovery 4 (9), 1036-1045, 2014
|Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer|
FJ Lagerwaard, NE Verstegen, CJA Haasbeek, BJ Slotman, MA Paul, ...
International Journal of Radiation Oncology* Biology* Physics 83 (1), 348-353, 2012
|Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors|
BC Kuenen, L Rosen, EF Smit, MRN Parson, M Levi, R Ruijter, ...
Journal of clinical oncology 20 (6), 1657-1667, 2002
|Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop|
R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ...
Journal of Thoracic Oncology 5 (10), 1706-1713, 2010
|Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort|
J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ...
Journal of clinical oncology 33 (9), 992-999, 2015